Trial · NCT00071721
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician | Valproate | 25 | Participants | ||
| Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician | Placebo | 29 | Participants | ||
| Cognitive Performance Assessed by the Alzheimer's Disease Assessment Scale-cognitive Subtest (ADAS-cog) | Valproate | 42.3 | Standard Deviation 14.3 | Units on a scale | |
| Cognitive Performance Assessed by the Alzheimer's Disease Assessment Scale-cognitive Subtest (ADAS-cog) | Placebo | 41.9 | Standard Deviation 14.4 | Units on a scale | |
| Functional Performance Assessed by the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory | Valproate | 35.1 | Standard Deviation 20.3 | Units on a scale | |
| Functional Performance Assessed by the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory | Placebo | 41.0 | Standard Deviation 14.81 | Units on a scale | |
| Global Severity of Dementia Using the CDR Sum of Boxes | Valproate | 12.0 | Standard Deviation 4.1 | Units on a scale | |
| Global Severity of Dementia Using the CDR Sum of Boxes | Placebo | 11.5 | Standard Deviation 3.7 | Units on a scale | |
| Agitation Measured by the Cohen-Mansfield Agitation Inventory (CMAI), Community Version | Valproate | 10.6 | Standard Deviation 11.6 | Units on a scale | |
| Agitation Measured by the Cohen-Mansfield Agitation Inventory (CMAI), Community Version | Placebo | 12.1 | Standard Deviation 10.9 | Units on a scale | |
| Participant's Clinical Condition or Endpoint Assessed With the ADCS-Clinical Global Impression of Change (ADCS-CGIC) | Valproate | 5.7 | Standard Deviation 0.9 | Units on a scale | |
| Participant's Clinical Condition or Endpoint Assessed With the ADCS-Clinical Global Impression of Change (ADCS-CGIC) | Placebo | 5.5 | Standard Deviation 1.1 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00071721/results